English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsBusinessStocksIpca Laboratories share price falls 2.11% in today's trading

    Ipca Laboratories share price falls 2.11% in today's trading

    Ipca Laboratories' shares were trading at Rs 1,342.30, a decrease of 2.11% in Monday's session.

    Alpha Desk
    September 29, 2025 / 12:43 IST
    Disclaimer This is an AI-assisted live blog with updates from multiple sources Disclaimer
    FIIs net sell Indian equities worth Rs 5688 crore while DIIs net buy Rs 5,843 crore on September 26

    Stock market today

     
     
    live
    • bselive
    • nselive
    Volume
    Todays L/H
    More

    Shares of Ipca Laboratories declined by 2.11% to Rs 1,342.30 in Monday's session. The stock is a constituent of the Nifty Midcap 150 index.

    Financial Performance:

    Ipca Laboratories' consolidated financial performance shows the following trends:

    Quarterly Results:

    HeadingJun 2024Sep 2024Dec 2024Mar 2025Jun 2025
    RevenueRs 2,092.63 CroreRs 2,354.90 CroreRs 2,245.37 CroreRs 2,246.69 CroreRs 2,308.85 Crore
    Net ProfitRs 198.98 CroreRs 245.44 CroreRs 277.33 CroreRs 65.78 CroreRs 234.42 Crore
    EPS7.589.059.782.679.19

    The revenue for Ipca Laboratories has seen a fluctuating trend over the last five quarters, with a recent increase to Rs 2,308.85 Crore in June 2025. Net profit also varied, with a significant drop in March 2025, followed by a recovery in June 2025.

    Annual Results:

    Heading20212022202320242025
    RevenueRs 5,419.99 CroreRs 5,829.79 CroreRs 6,244.32 CroreRs 7,705.04 CroreRs 8,939.59 Crore
    Net ProfitRs 1,148.84 CroreRs 910.95 CroreRs 491.93 CroreRs 529.21 CroreRs 787.53 Crore
    EPS45.0134.8518.5825.8235.14
    BVPS371.79219.51233.16304.57273.88
    ROE24.2416.098.068.6410.61
    Debt to Equity0.050.140.250.220.19

    The annual results show a consistent increase in revenue from 2021 to 2025. Although net profit declined between 2021 and 2023, it has since recovered. The debt-to-equity ratio has remained relatively stable.

    Cash Flow:

    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
    Operating ActivitiesRs 1,321 CroreRs 944 CroreRs 805 CroreRs 856 CroreRs 1,090 Crore
    Investing ActivitiesRs -869 CroreRs -1,291 CroreRs -725 CroreRs -855 CroreRs -520 Crore
    Financing ActivitiesRs -282 CroreRs -552 CroreRs 507 CroreRs 426 CroreRs -305 Crore
    OthersRs 0 CroreRs 76 CroreRs 0 CroreRs 4 CroreRs 0 Crore
    Net Cash FlowRs 168 CroreRs -823 CroreRs 588 CroreRs 431 CroreRs 263 Crore
    Balance Sheet:
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
    Share CapitalRs 25 CroreRs 25 CroreRs 25 CroreRs 25 CroreRs 25 Crore
    Reserves & SurplusRs 6,923 CroreRs 6,306 CroreRs 5,816 CroreRs 5,466 CroreRs 4,676 Crore
    Current LiabilitiesRs 2,386 CroreRs 2,355 CroreRs 1,805 CroreRs 1,465 CroreRs 1,160 Crore
    Other LiabilitiesRs 2,425 CroreRs 2,413 CroreRs 978 CroreRs 681 CroreRs 206 Crore
    Total LiabilitiesRs 11,760 CroreRs 11,101 CroreRs 8,626 CroreRs 7,638 CroreRs 6,068 Crore
    Fixed AssetsRs 4,798 CroreRs 4,805 CroreRs 2,853 CroreRs 2,669 CroreRs 2,260 Crore
    Current AssetsRs 6,268 CroreRs 5,538 CroreRs 5,189 CroreRs 4,457 CroreRs 3,436 Crore
    Other AssetsRs 694 CroreRs 756 CroreRs 583 CroreRs 511 CroreRs 370 Crore
    Total AssetsRs 11,760 CroreRs 11,101 CroreRs 8,626 CroreRs 7,638 CroreRs 6,068 Crore
    Contingent LiabilitiesRs 613 CroreRs 303 CroreRs 2,125 CroreRs 274 CroreRs 369 Crore
    Ratios:
    Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
    Basic EPS (Rs.)45.0134.8518.5825.8235.14
    Diluted Eps (Rs.)45.0134.8518.5821.5729.08
    Book Value [Excl. Reval Reserve]/Share (Rs.)371.79219.51233.16304.57273.88
    Dividend/Share (Rs.)8.004.004.004.004.00
    Face Value21111
    Gross Profit Margin (%)29.6523.5916.8518.7620.34
    Operating Margin (%)25.7919.6112.6614.1215.89
    Net Profit Margin (%)21.1915.627.876.868.80
    Return on Networth / Equity (%)24.2416.098.068.6410.61
    ROCE (%)28.4818.5211.5912.4415.15
    Return On Assets (%)18.7811.575.464.936.27
    Current Ratio (X)2.963.042.872.352.63
    Quick Ratio (X)1.591.771.911.301.55
    Debt to Equity (x)0.050.140.250.220.19
    Interest Coverage Ratios (X)177.79178.9123.1110.4621.42
    Asset Turnover Ratio (%)0.910.800.770.780.78
    Inventory Turnover Ratio (X)1.100.960.951.053.55
    3 Yr CAGR Sales (%)28.9924.3015.9019.2323.83
    3 Yr CAGR Net Profit (%)117.1443.23-10.30-32.13-7.02
    P/E (x)21.1530.5843.6147.9242.74
    P/B (x)5.134.903.524.965.48
    EV/EBITDA (x)14.9619.7319.2323.4522.26
    P/S (x)4.454.623.294.084.26
    Corporate Actions:

    Ipca Laboratories announced a final dividend of Rs 2.00 per share (200%) on May 29, 2025, with an effective date of August 05, 2025. Additionally, the company had a stock split on January 10, 2022, where the old face value of Rs 2 was split into a new face value of Rs 1. A bonus issue was announced on October 27, 2004, with a bonus ratio of 1:1 and an ex-bonus date of January 28, 2005.

    Ipca Laboratories' shares were trading at Rs 1,342.30, a decrease of 2.11% in Monday's session.

    Alpha Desk
    first published: Sep 29, 2025 12:43 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347